HAMP and Alzheimer disease: The immunohistochemical analysis of Hepcidin revealed that it was reduced in the AD model group compared with the C57 group, and DFO and active compounds groups displayed increased levels of IOD when compared with the AD model group (Figure 6A and 6B, P<0.05).